8-K: Foghorn Therapeutics Q1 2026 Update: Pipeline Progress & Financials

Foghorn Therapeutics announced its first-quarter 2026 financial results and provided an update on its clinical and preclinical programs, highlighting progress in its FHD-909 collaboration with Lilly and advancements in its degrader programs.

Summary

• Foghorn Therapeutics reported financial results for the quarter ended March 31, 2026, with collaboration revenue of $3.3 million, down from $6.0 million in the prior year's quarter.
• Research and development expenses decreased to $18.3 million from $21.6 million, while general and administrative expenses fell to $6.6 million from $7.2 million.
• The company reported a net loss of $19.9 million for the quarter, compared to a net loss of $18.8 million in the same period of 2025.
• As of March 31, 2026, Foghorn Therapeutics had $183.6 million in cash, cash equivalents, and marketable securities, with a projected cash runway into the first half of 2028.
• The lead program, FHD-909, a selective SMARCA2 inhibitor, is on track with its Phase 1 dose-escalation trial, with preclinical data showing potential for robust and durable regression when combined with an anti-PD-1 antibody.
• The company is advancing its selective CBP degrader, FHT-171, for ER+ breast cancer, with an IND anticipated in 2027.
• Selective EP300 degraders are also advancing, with INDs anticipated in 2027 for potential use in multiple myeloma and other hematological malignancies.
• Preclinical data for selective ARID1B degraders show robust degradation and potential for oral bioavailability, with in vivo proof of concept expected in 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, with significant progress in key pipeline programs and a strong financial position, despite a slight increase in net loss and a decrease in collaboration revenue due to timing.

Positives

• Strong cash position of $183.6 million as of March 31, 2026, providing runway into the first half of 2028.
• FHD-909 Phase 1 trial is on track, with promising preclinical combination data with anti-PD-1 antibodies.
• Advancement of FHT-171 (selective CBP degrader) with IND anticipated in 2027 for ER+ breast cancer.
• Advancement of selective EP300 degraders with INDs anticipated in 2027 for hematological malignancies.
• Positive preclinical data for selective ARID1B degraders, showing robust degradation and potential for oral bioavailability.
• Optimization of a long-acting injectable formulation for FHT-171.
• The company continues to invest in its chromatin biology and degrader platform, exploring new modalities like induced proximity.

Negatives

• Collaboration revenue decreased to $3.3 million from $6.0 million in the first quarter of 2025, primarily due to the timing of work under the Lilly Collaboration Agreement.
• Net loss increased to $19.9 million for the quarter ended March 31, 2026, from $18.8 million in the prior year's quarter.
• Research and development expenses, while decreased year-over-year, remain substantial at $18.3 million.
• The company has a significant stockholders deficit of $(76.4) million as of March 31, 2026.

Risks

• The company's clinical and preclinical programs are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Actual results may differ materially from forward-looking statements due to various regional, national, or global political, economic, business, competitive, market, and regulatory conditions.
• Risks related to clinical trials, including enrollment, efficacy, and safety.
• Dependence on collaborations, such as the one with Lilly, for development and commercialization.
• Challenges in developing selective drugs for targets with high homology to other proteins, such as CBP and EP300.
• Potential for dose-limiting toxicities associated with dual inhibition strategies.
• Intellectual property protection and enforcement for its platform and product candidates.

Future Outlook

The company anticipates advancing its FHD-909 program in collaboration with Lilly, with IND-enabling studies for its selective CBP and EP300 degraders expected in 2026 and IND filings anticipated in 2027. The company projects a cash runway into the first half of 2028.

Management Comments

• "Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA4 mutations, where outcomes remain especially poor and deteriorate with later lines of therapy."
• "At this years American Association for Cancer Research (AACR) Annual Meeting, we presented compelling preclinical data demonstrating the potential of FHD-909 in combination with an anti-PD-1 antibody to drive complete, durable tumor regression and anti-tumor immune memory."
• "Across our wholly owned pipeline, we reported new preclinical data highlighting strong anti-tumor activity and tolerability for our Selective CBP degrader FHT-171 in heavily pretreated ER+ breast cancer models, improved safety and efficacy versus clinical benchmark for our Selective EP300 degrader in multiple myeloma, and robust target degradation with potential for oral bioavailability for our cereblon-based selective ARID1B degraders."
• "Together, these programs expand our reach in difficult-to-treat cancers, and we look forward to sharing further progress throughout the year."

Industry Context

StockSavvy.ai notes that Foghorn Therapeutics is operating in the highly competitive and innovative oncology drug development space, focusing on novel mechanisms like chromatin regulation and protein degradation. Their progress with FHD-909 in collaboration with Lilly, a major pharmaceutical player, positions them to potentially address significant unmet needs in difficult-to-treat cancers like NSCLC. The advancement of their degrader programs also aligns with a growing trend in the pharmaceutical industry towards targeted protein degradation therapies.

Comparison to Industry Standards

• The preclinical data for FHD-909 in combination with an anti-PD-1 antibody, demonstrating complete and durable regression and immune memory, sets a high bar for potential combination therapies in oncology.
• The selective EP300 degrader program shows superior anti-tumor activity and a better safety profile compared to the clinical benchmark dual CBP/EP300 inhibitor, inobrodib, in multiple myeloma models.
• The development of long-acting injectable formulations, such as for FHT-171, aligns with industry trends aiming to improve patient compliance and convenience.
• The company's focus on genetically defined patient populations, such as SMARCA4-mutated NSCLC and ARID1A-mutated cancers, reflects a precision medicine approach that is becoming a standard in modern oncology drug development.

Stakeholder Impact

• Shareholders: Continued pipeline development and potential for future value creation, supported by a strong cash position. The slight increase in net loss may be a concern for some.
• Employees: Continued investment in R&D suggests ongoing employment opportunities and focus on innovation.
• Collaborators (Lilly): Progress in the FHD-909 program is a positive development for the strategic partnership.
• Patients: Advancements in novel therapies for difficult-to-treat cancers offer potential new treatment options.

Next Steps

• Continue enrollment in the Phase 1 multi-center trial of FHD-909.
• Evaluate FHD-909 in combination studies in the front-line setting of NSCLC, pending a decision to move into dose expansion.
• Complete IND-enabling studies for selective CBP and EP300 degraders in 2026.
• File INDs for selective CBP and EP300 degraders in 2027.
• Achieve in vivo proof of concept for selective ARID1B degraders in 2026.
• Continue to advance the chromatin biology and degrader platform.

Key Dates

Recommendation

The company shows strong progress in its pipeline and maintains a healthy cash position, which are positive indicators. However, the slight increase in net loss and the decrease in collaboration revenue warrant a cautious approach. The company is still in the clinical-stage, and significant milestones are ahead, making it a 'hold' for now, awaiting further clinical data and regulatory progress.

Keywords

Foghorn Therapeutics, FHTX, 8-K, Biotechnology, Oncology, Clinical Trials, Drug Development, SEC Filing